VM4 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Low Leverage / Solid Balance SheetVery low debt-to-equity (~2%–4%) gives Vanda structural financial flexibility to fund launches, support commercial ramp and absorb R&D volatility without immediate refinancing risk. This lowers insolvency risk and preserves optionality for strategic investments or partnerships over the next several quarters.
Revenue Rebound And Raised 2026 GuidanceA large TTM revenue rebound and an upwardly revised 2026 guide indicate recovering commercial traction and better demand visibility. Sustained top-line momentum supports funding of launches and pipeline work, improving forecastability of revenue-driven cash inflows over the coming 2–6 months.
Fanapt Momentum & Commercial BuildStrong Fanapt prescription growth and a near-doubling of the sales force are durable commercial advantages: they amplify market coverage, physician engagement and prescription penetration. If sustained, this scale in the field can drive predictable recurring product sales and improve life-cycle economics.
Bears Say
Persistent Negative Cash FlowConsecutive years of negative operating and free cash flow signal structural cash burn despite revenue gains. Continued negative cash generation increases reliance on cash reserves or financing, constrains reinvestment flexibility and elevates execution risk for launches and late‑stage programs.
Widening Losses & Higher Operating ExpensesGrowing net losses and rising SG&A/launch costs indicate the company is investing heavily to commercialize products but eroding near‑term profitability. If revenue acceleration lags expectations, higher fixed operating costs could prolong negative earnings and pressure equity and cash reserves.
Product Concentration & Hetlioz ErosionSignificant decline in Hetlioz from generic entry highlights dependence on a few brands for revenue. Product concentration makes overall revenue and cash flow vulnerable to competitive losses; successful replacement by new launches is required to sustain long‑term revenue stability.
Vanda News
VM4 FAQ
What was Vanda Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Vanda Pharmaceuticals’s market cap?
Vanda Pharmaceuticals’s market cap is CHF255.13M.
When is Vanda Pharmaceuticals’s upcoming earnings report date?
Vanda Pharmaceuticals’s upcoming earnings report date is Aug 05, 2026 which is in 8 days.
How were Vanda Pharmaceuticals’s earnings last quarter?
Vanda Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$0.672 earnings per share for the quarter, missing the consensus estimate of -$0.564 by -$0.108.
Is Vanda Pharmaceuticals overvalued?
According to Wall Street analysts Vanda Pharmaceuticals’s price is currently Undervalued.
Does Vanda Pharmaceuticals pay dividends?
Vanda Pharmaceuticals does not currently pay dividends.
What is Vanda Pharmaceuticals’s EPS estimate?
Vanda Pharmaceuticals’s EPS estimate is -0.48.
How many shares outstanding does Vanda Pharmaceuticals have?
Currently, no data Available
What happened to Vanda Pharmaceuticals’s price movement after its last earnings report?
Vanda Pharmaceuticals reported an EPS of -$0.672 in its last earnings report, missing expectations of -$0.564. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:VM4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vanda Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF15.20 (― Downside)
CHF15.20 (― Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.40%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
VM4 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive commercial and pipeline momentum story: Fanapt demonstrated strong prescription growth and the company launched Nirius via a novel direct‑to‑consumer model while securing FDA approval for Dysanti and advancing imsidolimab toward potential year‑end regulatory action. Management raised 2026 revenue guidance and outlined multiple upcoming Phase 3 readouts that could be value drivers. Offsetting these positives are a materially larger Q1 net loss, increased operating expenses, a significant cash decline and ongoing Hetlioz erosion from generics, plus some development and recruitment risks for certain programs. Overall, commercial and regulatory catalysts appear to outweigh near‑term financial pressures.View all CH:VM4 earnings summariesVM4 Stock 12 Month Forecast
Average Price Target
$15.20
Omeros
―
Aldeyra Therapeutics
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Alector
―